Literature DB >> 11332679

Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.

N Kuyucu1, C Kara, A Bakirtaç, T Teziç.   

Abstract

Pentavalent antimony is still the drug of choice in the treatment of visceral leishmaniasis. Pantavalent antimony can cause a wide range of adverse effects, the most serious of which are cardiotoxicity and hepatotoxicity. Acute pancreatitis is a rarely reported adverse effect. An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11332679     DOI: 10.1097/00006454-200104000-00021

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  3 in total

1.  Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil.

Authors:  Y M Brustoloni; R V Cunha; L Z Cônsolo; A L L Oliveira; M E C Dorval; E T Oshiro
Journal:  Infection       Date:  2010-05-28       Impact factor: 3.553

2.  Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations.

Authors:  Dianna Wolfe; Salmaan Kanji; Fatemeh Yazdi; Pauline Barbeau; Danielle Rice; Andrew Beck; Claire Butler; Leila Esmaeilisaraji; Becky Skidmore; David Moher; Brian Hutton
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

3.  PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS.

Authors:  Marcelo Rosandiski Lyra; Sonia Regina Lambert Passos; Maria Inês Fernandes Pimentel; Sandro Javier Bedoya-Pacheco; Cláudia Maria Valete-Rosalino; Erica Camargo Ferreira Vasconcellos; Liliane Fatima Antonio; Mauricio Naoto Saheki; Mariza Mattos Salgueiro; Ginelza Peres Lima Santos; Madelon Noato Ribeiro; Fatima Conceição-Silva; Maria Fatima Madeira; Jorge Luiz Nunes Silva; Aline Fagundes; Armando Oliveria Schubach
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-09-22       Impact factor: 1.846

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.